β 2-ADRENOCEPTOR GENE POLYMORPHISM AND THE COURSE OF ASTHMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Asthmatic patients without the 16ArgArg+ genotype were recorded to develop exacerbations more frequently if they do not receive adequate anti-inflammatory therapy. The use of inhaled glucocorticosteroids, as well as long-acting β-adrenomimetics for planned therapy in the patients can substantially reduce the number of exacerbations.

Full Text

Restricted Access

About the authors

N. Chlchkova

I.M. Sechenov First Moscow State Medical University; Center of Clinical Pharmacology, Research Center for Examination of Medical Products, Moscow, Ministry of Health of Russia

Email: nvchichkova@mail.ru
MD; Professor

V. Flsenko

I.M. Sechenov First Moscow State Medical University; Center of Clinical Pharmacology, Research Center for Examination of Medical Products, Moscow, Ministry of Health of Russia

Academician of the Russian Academy of Medical Sciences; Professor

V. Kukes

I.M. Sechenov First Moscow State Medical University; Center of Clinical Pharmacology, Research Center for Examination of Medical Products, Moscow, Ministry of Health of Russia

Academician of the Russian Academy of Medical Sciences

I. Ignatyev

I.M. Sechenov First Moscow State Medical University; Center of Clinical Pharmacology, Research Center for Examination of Medical Products, Moscow, Ministry of Health of Russia

Candidate of Biological Sciences

References

  1. Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA), пересмотр 2011 г. Пер. с англ. / М.: Атмосфера, 2012; 108 с.
  2. Ненашева Н.М. Клинические фенотипы атопической бронхиальной астмы и дифференциальная тактика диагностики и лечения. Дис.. д-ра мед. наук. М., 2008; 325 с.
  3. Саркисян Л.К. Течение бронхиальной астмы в зависимости от полиморфизма гена β2-адренорецептора Arg16Gly. Дис.. канд. мед. наук. 2006; 115 с.
  4. Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Клиническая фармакогенетика / М.: ГЭОТАР-Медиа. 2007; 248.
  5. Трофимов В.И., Миронова Ж.А., Янчина Е.Д. и др. Фармакогенетические аспекты тяжелой астмы // Пульмонология. - 2008; 2: 111-6.
  6. Фисенко В.П., Чичкова Н.В. Бета-адреномиметики: эффективность и безопасность при бронхиальной астме и хронической обструктивной болезни легких // Врач. - 2007; 7: 37-9.
  7. Фрейдин М.Б., Огородова Л.М., Бердникова Н.Г. и др. Генетика бронхиальной астмы. В кн. Генетика бронхолегочных заболеваний. Под ред. А.Г. Чучалина / М.: Атмосфера, 2010; с. 78-104.
  8. Contopoulos-Ioannidis D., Manoli E., Ioannidis J. Meta-analysis of the association of beta-adrenergic receptor polymorphisms with asthma phenotypes // J. Allerg. Clin. Immunol. - 2005; 115 (5): 963-72.
  9. Hizawa N. Pharmacogenetics of beta (2)-agonosts // Allerg. Intern. - 2011; 60 (3): 239-46.
  10. Israel E., Hinchilli V., Ford J. et al. Use of regularluy scheduled albuterol treatment in asthma: genotype stratified, randomised placebo-controlled crossover trial. // Lancet. - 2004; 364 (9444): 1505-12.
  11. Israel E., Drazen J., Liggett S. et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma // Am. J. Resp. Crit. Care Med. - 2000; 162 (1): 75-80.
  12. Martinez F., Graves P., Baldini M. et al. Association between genetic polymorphisms of the beta2-adrenoreceptor and response to albuterol in children with and without a history of wheezing // J. Clin. Invest. - 1997; 100 (12): 3184-8.
  13. Nelson H., Weiss S., Bleeker E. et al. The salmeterol multicenter asthma research trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol // Chest. - 2006; 129 (1): 15-26.
  14. Obeidat M., Hall I. Cenetic of complex respiratory diseases: inplications for pathophysiology and pharmacology studies // Br. J. Pharmacol. - 2011; 163 (1): 96-105.
  15. Ober C., Yao T. The genetic of asthma and allergic disease: a 21st century perspective // Immunol. Rev. - 2011; 242 (1): 10-30.
  16. Pascual R., Bleecker E. Pharmacogenetics of asthma // Curr. Opin. Pharmacol. - 2010; 10 (3): 226-35.
  17. Rebordosa C., Kogevinas M., Guerra S. et al. ADRB2 Gly16Arg polymorphism, asthma и control and lung function decline // Eur. Resp. J. -2011; 38 (5): 1029-35.
  18. Reed C. Abnormal autonomic mechanisms in asthma // J. Allerg. Clin. Immunol. - 1974; 54 (1): 34-41.
  19. Reihsaus E., Innis M., MacIntyre N. et al. Mutations in the gene encoding for the beta2-adrenergic receptor in normal and asthmatic subjects // Am. J. Respir. Cell. Mol. Biol. - 1993; 8 (3): 334-9.
  20. Salpeter S., Buckley N., Ormiston T. et al. Meta-analysis: effect of long-acting beta2-agonists on severe asthma exacerbations and asthma-related deaths // Ann. Intern. Med. - 2006; 144 (2): 904-12.
  21. Siroux V., Garcia-Aymerich J. The investigation of asthma phenotypes // Curr. Opin. Allerg. Clin. Immonol. - 2011; 11 (1): 393-9.
  22. Szentivanyi A. The beta-adrenergic theory of the atopic abnormality in bronchial asthma // J. Allergy. - 1968; 42: 203-42.
  23. Taylor D., Drazen J., Herbison G. et al. Asthma exacerbation during long term beta-agonist use: influence of beta (2) adrenoreceptor polymorphism // Thorax. - 2000; 55 (9): 762-7.
  24. Vercelli D. Discovering susceptibility genes for asthma and allergy // Nat. Rev. Immunol. - 2008; 8: 162-82.
  25. Walker J., Penn R., Hanania N. et al. New perspectives regarding beta-adrenoreceptor ligands in the treatment of asthma // Br. J. Pharmacol. - 2011; 163 (1): 18-28.
  26. Weiss S. New approches to personalized medicine for asthma: where are we? // J. Allerg. Clin. Immunol. - 2012; 129 (2): 327-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies